Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

Home/Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

Clinical Trials, Pharma & Healthcare

Publication ID:

GDA03171323

Publication Date:

March 31, 2017

Pages:

203

Publisher:

GlobalData

Region:

Global

$2,500.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

Summary

GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 27
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Amyotrophic Lateral Sclerosis 35
Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 35
Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis 35
Mar 01, 2017: BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn Available to Patients as a Hospital Exemption Product 35
Feb 27, 2017: BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success 36
Feb 16, 2017: City of Hope to Manufacture NurOwn for Brainstorm's Phase 3 ALS Clinical Trial 36
Feb 08, 2017: Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS 37
Jan 30, 2017: BrainStorm Announces Validation of NurOwn Cryopreservation Process 37
Jan 24, 2017: Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases 37
Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis 37
Clinical Trial Profile Snapshots 39
Appendix 201
Abbreviations 201
Definitions 201
Research Methodology 202
Secondary Research 202
About GlobalData 203
Contact Us 203
Source 203

List of Tables
List of Tables
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region, 2017* 6
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 20
Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2017* 23
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

List of Figures
List of Figures
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 14
Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 15
Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 19
Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 24
Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34
GlobalData Methodology 202

Companies Covered

Cytokinetics Inc
Knopp Biosciences LLC
F. Hoffmann-La Roche Ltd
Teva Pharmaceutical Industries Ltd
Newron Pharmaceuticals SpA
Biogen Inc
BrainStorm Cell Therapeutics Inc
Neuralstem Inc
Flex Pharma Inc
Aeolus Pharmaceuticals Inc

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".